Evaluating the clinical significance of serum HE4 levels in lung cancer and pulmonary tuberculosis

International Journal of Tuberculosis and Lung Disease

Volumn 17, Issue 10, 2013, Pages 1346-1353

  Liu, W ^a   Yang, J ^a,b   Chi, P D ^a   Zheng, X ^a   Dai, S Q ^a   Chen, H ^a   Xu, Bang Lao ^b   Liu, Wan Li ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b GUANGZHOU FIRST PEOPLE'S HOSPITAL   (China)

Author keywords

HE4; Lung cancer; Non small cell lung cancer; PTB

Indexed keywords

HUMAN EPIDIDYMIS PROTEIN 4;

ADULT; AGE; AGED; ARTICLE; BLOOD SAMPLING; CANCER GROWTH; CANCER PROGNOSIS; CANCER STAGING; CONTROLLED STUDY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; PNEUMONIA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY; SMOKING; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; CASE-CONTROL STUDIES; DIAGNOSIS, DIFFERENTIAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LOGISTIC MODELS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PNEUMONIA; PROGNOSIS; PROTEINS; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; TUBERCULOSIS, PULMONARY; TUMOR MARKERS, BIOLOGICAL;

EID: 84884648553     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.13.0058     Document Type: Article

References (23)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun M J. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-249.
2. Parkin D M, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
3. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007; 8: 581-592.
4. Pass H I, Carbone D P, Johnson D H, Minna J D, Scagliotti G V, Turrisi III A T. Principles and practice of lung cancer. 4th ed. Philadelphia, PA, USA: Lippincott Williams & Wilkins, 2009.
5. Tas F, Aydiner A, Topuz E, Yasasever V, Karadeniz A, Saip P. Utility of the serum tumor markers: CYFRA 21.1, carcinoembryonic antigen (CEA), and squamous cell carcinoma antigen (SCC) in squamous cell lung cancer. J Exp Clin Cancer Res 2000; 19: 477-481.
6. Brower V. Biomarker studies abound for early detection of lung cancer. J Natl Cancer Inst 2009; 101: 11-13.
7. Hellström I, Raycraft J, Hayden-Ledbetter M, et al. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res 2003; 63: 3695-3700.
8. Drapkin R, von Horsten H H, Lin Y, et al. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res 2005; 65: 2162-2169.
9. Bignotti E, Ragnoli M, Zanotti L, et al. Diagnostic and prognostic impact of serum HE4 detection in endometrial carcinoma patients. Br J Cancer 2011; 104: 1418-1425.
10. Huhtinen K, Suvitie P, Hiissa J, et al. Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts. Br J Cancer 2009; 100: 1315-1319.
11. Kong S Y, Han M H, Yoo H J, et al. Serum HE4 level is an independent prognostic factor in epithelial ovarian cancer. Ann Surg Oncol 2012; 19: 1707-1712.
12. Bandiera E, Romani C, Specchia C, et al. Serum human epididymis protein 4 and risk for ovarian malignancy algorithm as new diagnostic and prognostic tools for epithelial ovarian cancer management. Cancer Epidemiol Biomarkers Prev 2011; 20: 2496-2506.
13. Kalogera E, Scholler N, Powless C, et al. Correlation of serum HE4 with tumor size and myometrial invasion in endometrial cancer. Gynecol Oncol 2012; 124: 270-275.
14. Yamashita S, Tokuishi K, Hashimoto T, et al. Prognostic significance of HE4 expression in pulmonary adenocarcinoma. Tumour Biol 2011; 32: 265-271.
15. Tokuishi K, Yamashita S, Ohbo K, Kawahara K. Splice variant HE4-V3 expression is associated with favorable prognosis in pulmonary adenocarcinoma. Tumour Biol 2012; 33: 103-109.
16. Iwahori K, Suzuki H, Kishi Y, et al. Serum HE4 as a diagnostic and prognostic marker for lung cancer. Tumour Biol 2012; 33: 1141-1149.
17. Escudero J M, Auge J M, Filella X, Torne A, Pahisa J, Molina R. Comparison of serum human epididymis protein 4 with cancer antigen 125 as a tumor marker in patients with malignant and nonmalignant diseases. Clin Chem 2011; 57: 1534- 1544.
18. Sobin L H, Gospodarowicz M K, Wittekind C, eds. TNM classification of malignant tumors. 7th ed. Oxford, UK: Wiley- Blackwell, 2009.
19. Travis W D, Colby T V, Corrin B, Shimosato Y, Brambilla E; In collaboration with Sobin L H and pathologists from 14 countries. World Health Organization international histological classification of tumours. Histological typing of lung and pleural tumours. 3rd ed. Berlin, Germany: Springer-Verlag, 1999.
20. Ministry of Health of the People's Republic of China. Diagnostic criteria for pulmonary tuberculosis (WS 288-2008). Beijing, China: China National Accreditation Service, 2008.
21. Bingle L, Cross S S, High A S, et al. High WFDC2 (HE4): A potential role in the innate immunity of the oral cavity and respiratory tract and the development of adenocarcinomas of the lung. Respir Res 2006; 7: 61.
22. Taguchi A, Politi K, Pitteri S J, et al. Lung cancer signatures in plasma based on proteome profiling of mouse tumor models. Cancer Cell 2011; 20: 289-299.
23. Li J, Chen H, Mariani A, et al. HE4 (WFDC2) promotes tumor growth in endometrial cancer cell lines. Int J Mol Sci 2013; 14: 6026-6043.